<DOC>
	<DOCNO>NCT02453932</DOCNO>
	<brief_summary>This ongoing study aim evaluate efficacy safety Tianzhi granule mild moderate vascular dementia reasonable design .</brief_summary>
	<brief_title>Efficacy Safety Tianzhi Granule Mild Moderate Vascular Dementia</brief_title>
	<detailed_description>This study 24-weeks , multicenter , randomize , double-blind , double- placebo , parallel control phase III trial carry 19 center around China . The study population include mild moderate VaD patient ( plan total 637 ) age 45-85 gender . Participants randomly allocate TZK ( 15g/d ) placebo identify donepezil , donepezil ( 5mg/d ) placebo identify TZK , placebo identify TZK placebo identify donepezil 24-weeks double-blind treatment period 12-weeks follow period withdrawal experimental medication . The primary outcome measure change baseline Vascular Dementia Assessment Scale-Cognitive Subscale Clinician 's Interview-Based Impression Change-Plus carer Interview . The secondary outcome change baseline Mini-Mental State Examination , Activity Daily Living Scale , Clock Drawing Test , Trail Making Test Neuropsychiatric Inventory . Safety assess observe side effect adverse reaction entire treatment period . Statistical analysis conduct accord per-protocol population intend-to-treat population safety analyze safety set .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inpatients outpatient meet diagnostic criterion probable VaD establish accord Diagnostic Statistical Manual Mental Disorders ( fourth edition ) （DSMⅣ） National Institute Neurological Disorders Stroke Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( NINDSAIREN ) eligible participate , diagnosis mild moderate vascular dementia ; Chinesespeaking patient age ≥45 and≤85 year old gender ; weigh 45 90kg ; fully conscious ; MMSE score of≤26 ≥14 ; HIS score ≥7 ; adequate vision hear ability complete study test ; stable caregiver . Patients exclude enrollment meet following : medical history dementia type , like Alzheimer 's disease , Parkinson 's disease dementia , Huntington disease , Normal pressure hydrocephalus , et al ; major depression ( HAMD 17 items＞17 ) psychotic disorder ; acute stage cerebral hemorrhage subarachnoid hemorrhage ; hypothyroidism ; drug alcohol abuse ; epilepsy history ; myasthenia gravis history ; severe cardiovascular disease ( severe arrhythmia heart rate≥100 or≤60 time per min , leave bundle branch block , myocardial infarction within 3 month , systolic pressure≥180mmHg ≤90mmHg ) ; severe liver kidney dysfunction ( alanine aminotransferase＞60 IU/L , aspartate transaminase＞60 IU/L serum creatinine ＞266μmol/L ) ; severe asthma chronic obstructive pulmonary disease ; gastrointestinal tract obstruction severe peptic ulcer ; glaucoma ; administration cholinesterase inhibitor , memantine nimodipine last month ; use sympathomimetic agent , antihistamine drug , antianxiety drug tranquilizer within 48h assessment ; use antipsychotic drug within 72h assessment ; participation clinical trial ; allergic history type medication use study .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Vascular dementia</keyword>
	<keyword>Tianzhi granule</keyword>
	<keyword>Herbal medicine</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>Three arm</keyword>
</DOC>